The Search for an Elusive Uniform Strategy for a Heterogeneous Disease: Lesson Learned?
Mené sur 324 patientes atteintes d'un cancer métastatique du sein, cet essai de phase III évalue, du point de vue de la survie sans progression et de la survie globale, une chimiothérapie d'entretien à base de paclitaxel et gemcitabine
As we advance toward an era of targeted therapies with the potential for longer disease control and overall survival (OS) for patients with metastatic breast cancer, the ringing success stories have thus far been largely confined to human epidermal growth factor receptor 2 (HER2)-positive disease. Despite one important trial (E21004) demonstrating an impressive improvement in progression-free survival (PFS) in HER2-negative metastatic breast cancer for the addition of bevacizumab to first-line taxane chemotherapy, subsequent trials failed to confirm this degree of benefit, and no survival benefit has been observed...
Journal of Clinical Oncology , éditorial en libre accès, 2013